Recurrent Disease Completed Phase 2 Trials for Docetaxel (DB01248)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01794845Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaTreatment